About Kurma Partners
Kurma Partners is a venture capital firm founded in 2009. It is primarily based out of Paris, France. As of May 2026, Kurma Partners is an active investor, having invested in 89 companies, with 3 new investments in the last 12 months. It primarily invests in Series A round in France based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series B round of Nuclidium Overall, Kurma Partners portfolio has seen 12 IPOs and 15 acquisitions including key companies like Adocia, Pharvaris and Stilla Technologies. A lot of funds co-invest with Kurma Partners, with names like Idinvest Partners sharing a substantial percentage of its portfolio. Kurma Partners has team of 19 people including 6 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 5 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Kurma Partners' List of Top Investments
Kurma Partners has a portfolio of 89 companies. Their most notable investments are in Pharvaris and Tacalyx.Their portfolio spans across France, Netherlands, Switzerland and 9 more locations. They have invested in Life Sciences, HealthTech, High Tech and 11 other sectors, across stages such as Series A, Seed and 5 more. Here is the list of top investments by Kurma Partners:1. Adocia
Developer of therapeutics for the treatment of diabetes and obesity. Its proprietary platform called the 'Biochaperone' enhances the effectiveness and safety of therapeutic proteins and enables easier usage on patients. Their clinical pipeline includes a unique formulation of PGDF-BB for the treatment of diabetic foot ulcers and insulin formulations for the treatment of diabetes.
Key facts about Adocia
2. Pharvaris
Pharvaris is a preclinical stage company developing orally deliverable drugs for hereditary angioedema (HAE). The lead candidate, PHA121 is a bradykinin B2 receptor competitive antagonist & demonstrated activity in bradykinin-mediated disease models. The company is advancing this molecule into IND-enabling studies.
Key facts about Pharvaris
- Founded Year: 2015
- Location: Leiden (Netherlands)
- Stage: Public
- Total Funding till date: $164M
- Employee Count: 155 as on Jun 30, 2026
- Investors: Foresite Capital, VenBio and 9 Others
- Latest Funding Round: Series C, Nov 18, 2020, $*****
- Highlight: Public
Developer of digital PCR solution for research. The system works on the principle of Crystal Digital PCR in a compact and reliable digital PCR solution with a single consumable. The device is assisted by Crystal Miner software for analyzing the generated data and identifying positive and negative droplets for all 3 fluorescence channels.
Key facts about Stilla Technologies
- Founded Year: 2013
- Location: Villejuif (France)
- Stage: Acquired
- Total Funding till date: $53.1M
- Employee Count: 84 as on Jun 30, 2026
- Investors: Partech Partners, Casdin Capital and 11 Others
- Latest Funding Round: Series B, Nov 23, 2021, $*****
- Highlight: Acquired
4. Nuevocor
Developer of genetic medicines for treating rare heart muscle conditions. These therapies target underlying mechanical defects in heart tissue to address disease progression. The focus remains on creating treatments for specific genetic cardiomyopathies that currently lack effective therapeutic options.
Key facts about Nuevocor
Developer of immunotherapeutic antibodies for the treatment of multiple diseases. It offers a new generation of proprietary immunomodulatory antibodies acting on both adaptive and innate immunity (notably gamma-delta T-cells). It offers therapeutics for cancer, infectious disease, and autoimmune disease.
Key facts about Imcheck Therapeutics
- Founded Year: 2015
- Location: Marseille (France)
- Stage: Acquired
- Total Funding till date: $185M
- Employee Count: 52 as on Jan 31, 2026
- Investors: Life Sciences Partners, Andera Partners and 16 Others
- Latest Funding Round: Grant (prize money), Aug 30, 2024, $*****
- Highlight: Acquired
Kurma Partners' Year-on-Year Investment Trends
Kurma Partners has invested in 89 companies over the last 16 years, with an average of 5 new investments annually in the last 10 years. In 2025, it made 14 investments, while as of May 2026, it has made 4 investments in this year. Its most recent first time investment was in Basis and most recent follow-on round was in Nuclidium.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 4 | 4 |
2025 | 8 | 6 | 14 |
2024 | 5 | 4 | 9 |
2023 | 4 | 3 | 7 |
2022 | 3 | 4 | 7 |
2021 | 7 | 6 | 13 |
2020 | 8 | 5 | 13 |
2019 | 4 | 7 | 11 |
2018 | 2 | 2 | 4 |
2017 | 8 | 2 | 10 |
Kurma Partners' Investments by Stage
Kurma Partners has made 26 investments in Series A stage with an average round size of $37.4M, 18 investments in Seed stage with an average round size of $10.3M and 13 investments in Series B stage with an average round size of $41.8M.Stage of entry | No. of Investments |
|---|---|
Series A | 26 |
Seed | 18 |
Series B | 13 |
Series C | 2 |
PE | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
Kurma Partners' Investments by Sector
Kurma Partners has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Internet of Things - Industry Applications. Notably, it has invested in 77 Tech companies, 72 Enterprise (B2B) companies, 16 Software companies and at least 15 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 51 |
High Tech | 14 |
HealthTech | 13 |
Enterprise Applications | 6 |
Internet of Things - Industry Applications | 4 |
Others | 18 |
Note: We have considered here, only first round of investments
Kurma Partners' Investments by Geography
Kurma Partners has made most investments in France (33), followed by Netherlands where it has made 5 investments.Country | No. of Investments |
|---|---|
France | 33 |
Netherlands | 5 |
Switzerland | 5 |
Germany | 4 |
Spain | 4 |
Others | 11 |
Note: We have considered here, only first round of investments
Kurma Partners' recent investments
Kurma Partners has made 4 investments in 2026 so far. Nuclidium and Tacalyx are the latest among them.Here are the most recent investments by Kurma Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 27, 2026 | Switzerland | Series B | 9172 | [+7] | |
Apr 29, 2026 | Germany | Seed | 5473 | ||
Mar 23, 2026 | Netherlands | Seed | 6573 | ||
Mar 02, 2026 | United States | Series A | 2182 | [+6] | |
Dec 22, 2025 | United States | Series A | 8062 | [+4] |
IPOs and Publicly Listed companies in Kurma Partners' Portfolio
12 of Kurma Partners' portfolio companies have become public. IO Biotech got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Nov 2021 at marketcap of $388M and Pharvaris got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $637M.Here are Kurma Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 05, 2021 | Jan 13, 2021 | Series B | 6108 | |
Feb 05, 2021 | 2015 | Series A | 8904 | |
Dec 15, 2020 | - | - | 4081 | |
Aug 23, 2019 | - | - | 7858 | |
Nov 16, 2017 | Jan 09, 2015 | Series B | 5122 |
Acquired companies in Kurma Partners' Portfolio
15 companies from Kurma Partners' portfolio have been acquired. The most recent acquisition was Memo Therapeutics in Jul 2026 by Ipsen for $*****.Here are Kurma Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 01, 2026 | May 07, 2024 | Series C | 5881 | |
Jan 13, 2026 | Jul 11, 2013 | Series B | 2948 | |
Dec 15, 2025 | May 02, 2017 | Series A | 3790 | |
Feb 14, 2025 | Nov 20, 2018 | Series A | 3392 | |
Mar 14, 2024 | Aug 06, 2019 | Series A | 8072 |
Team profile of Kurma Partners
Kurma Partners has a team of 19 members including 6 Partners, 1 Venture Partner and 2 Principals located in France and Germany. Kurma Partners' team does not sit on the board of any company as of now.Here is a list of top team members in Kurma Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | France | - | ||
Partner | Paris | - | ||
Partner | Paris | - | ||
Partner | Paris | - | ||
Partner | Paris | - | - | |
Partner | Munich | - | ||
Venture Partner | France | - | - | |
Principal | France | - | ||
Principal | France | - |
Co-investors of Kurma Partners
Over the past 16 years, 346 investors have co-invested in Kurma Partners's portfolio companies. This includes funds and angels.
- Invested before Kurma Partners: Europa, EIC Fund and 58 others have invested in rounds before Kurma Partners. There are 7 companies where Europa has invested before Kurma Partners and 4 companies where EIC Fund has invested before Kurma Partners.
- Top Co-investors of Kurma Partners: 157 investors entered a company along with Kurma Partners. These include investors like Idinvest Partners (24 companies).
- Invested after Kurma Partners: A total of 129 investors have invested in Kurma Partners's portfolio after their investments. Top Investors include Eurazeo (9 companies), European Investment Bank (6 companies) and Bpifrance (6 companies).
Recent News related to Kurma Partners
•
NUCLIDIUM AG Announces Closing of Series B Extension, Raising Total Round to CHF 105 MillionGlobeNewswire•May 27, 2026•Angelini Ventures, Nuclidium, DeepTech & Climate Fonds, Neva SGR and 5 others
•
Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the ClinicWebDisclosure•Apr 29, 2026•Tacalyx, HTGF, Eurazeo, Kurma Partners and 3 others
•
Kurma Partners closes €215 million Biofund IV to support European biotech venturesStartup Rise EU•Apr 24, 2026•Kurma Partners, Bpifrance, European Investment Fund, Bpifrance
•
Laigo Bio Closes €17M Seed FundingFinSMEs•Mar 23, 2026•Laigo Biotechnology, Biovance Capital, Kurma Partners
•
Medincell Announces Private PlacementFortuneo•Mar 05, 2026•MedinCell, Affinity Asset Advisors, Perceptive Advisors, Kurma Partners and 1 other
•
Alveus Therapeutics Raises $37M in Series A Extension FundingFinSMEs•Mar 02, 2026•Basis, Jeito, Avego, Omega Funds and 5 others
•
Andera Partners Co-leads $160M Series A for Alveus to Advance Obesity TherapiesWebDisclosure•Jan 08, 2026•Andera Partners, Alveus Pharma, New Rhein, Avego and 4 others
•
Laigo Bio Raises €11.5M in Seed FinancingFinSMEs•Dec 04, 2025•Laigo Biotechnology, Kurma Partners, Curie Capital, Argobio and 3 others
•
Adcytherix Raises €105 Million to Advance Antibody-Drug Conjugate PortfolioGlobeNewswire•Oct 16, 2025•Adcytherix, Bpifrance, Angelini Ventures, Citadel and 4 others
•
Step Pharma Completes €38 Million Series C FinancingGlobeNewswire•Oct 15, 2025•Bpifrance, Step Pharma, Kurma Partners, V-Bio Ventures and 1 other
